Background: Several studies have implicated the role of inflammation in the pathogenesis of lung damage in idiopathic interstitial pneumonias (IIPs). Investigations of inflammatory cells in IIP have show that eosinophils, neutrophils and T cells may be associated with a poorer prognosis. Objectives: The aim of our study was to map, by quantitative analysis, the number of inflammatory cells in the lung tissue of patients with non-specific interstitial pneumonia/non-specific interstitial pneumonia (NSIP/NSIP), acute interstitial pneumonia/diffuse alveolar damage (AIP/DAD) and idiopathic pulmonary fibrosis/usual interstitial pneumonia (IPF/UIP) and to correlate them with lung function tests and survival. Methods: After immunohistochemical staining, we quantified the content of inflammatory cells [macrophages, neutrophils (elastase+), plasma cells, and CD3, CD4 and CD8 T lymphocytes (TLs)] in 20 NSIP, 20 DAD and 20 UIP surgical lung biopsies. Results: The total density of inflammatory cells was significantly increased in DAD and NSIP when compared to UIP (p = 0.04). TLs were increased in DAD and NSIP when compared to UlP lungs (p < 0.05). The density of inflammatory cells in UIP showed significant differences in normal, intervening and dense fibrosis areas (p < 0.05). The most numerous cells infiltrating the mural fibrosis and honeycombing areas were plasma cells, neutrophils (elastase+), CD20+, CD3+, CD4+ and CD8+ (p < 0.05). In UIP, CD3+ TLs were directly correlated with forced expiratory volume in 1 s/forced vital capacity ratio × 100 (p = 0.05). CD68+ cells presented a significant positive correlation with the forced expiratory volume in 1 s (p = 0.04); neutrophil (elastase+) cells significantly correlated with residual volume (p = 0.02), residual volume/total lung capacity (p = 0.04) and carbon monoxide transfer factor (p = 0.03). The most important predictor of survival in UIP was CD3+ TLs (p = 0.05). Conclusion: The total density of inflammatory cells and lymphocytes presents a different distribution within the pulmonary parenchyma in AIP/DAD, NSIP/NSIP and IPF/UIP evolutionary adapted responses to injury. There is a localized distribution of inflammation in the normal, intervening and dense fibrosis areas of UIP for CD3+, associated with a lethal deterioration of the pulmonary function and poor survival. Our findings provide further evidence of the importance of inflammation in the pathophysiology of IIPs.

Keywords:
Idiopathic interstitial pneumonia, Infiltrating mononuclear cells, Morphometric analysis
1.
Katzenstein AL, Myers JL: Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301–1315.
2.
Nathan C: Points of control in inflammation. Nature 2002;420:846–852.
3.
Selman M, King TE, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136–151.
4.
Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517–525.
5.
Ishii H, Mukae H, Kadota J, Fujii T, Abe K, Ashitani J, Kohno S: Increased levels of interleukin-18 in bronchoalveolar lavage fluid of patients with idiopathic nonspecific interstitial pneumonia. Respiration 2005;72:39–45.
6.
Katzeenstein A, Zisman AD, Litzky AL, Nguyen TB, Kotloff MR: Usual interstitial pneumonia: histologic study of biopsia and explant specimens. Am J Surg Pathol 2002;26:1567–1577.
7.
Flaherty KR, Travis WD, Colby TV, Toewes GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL 3rd, Flint A, Lynch JP 3rd, Martinez FJ: Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:1722–1727.
8.
Tabuena RP, Nagai S, Tsutsumi T, Handa T, Minoru T, Mikuniya T, Shigematsu M, Hamada K, Izumi T, Mishima M: Cell profiles of bronchoalveolar lavage fluid as prognosticators of idiopathic pulmonary fibrosis/usual interstitial pneumonia among Japanese Patients. Respiration 2005;72:490–498.
9.
Riches WHD, Worthen GS, Augustin A, Lapadat R, Chan DE: Inflammation in the pathogenesis of interstitial lung disease; in Schwartz JM, King ET Jr (eds): Interstitial Lung Disease. Hamilton, Decker, 2003, pp 187–200.
10.
Kradin RL Divertie MB, Colvin RB, Ramirez J, Ryu J, Carpenter HA, Bhan AK: Usual interstitial pneumonia is a T-cell alveolitis. Clin Immunol Immunopathol 1986;40:224–235.
11.
Homolka J, Ziegenhagen MW, Gaede KI, Entzian P, Zissel G, Müller-Quernheim J: Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis. Respiration 2003;70:262–269.
12.
Antoniou KM, Alexandrakis M, Tzanakis N, Tsiligianni I, Tzortzaki EG, Siafakas NM, Bouros DE: Induced sputum versus bronchoalveolar lavage fluid in the evaluation of patients with idiopathic pulmonary fibrosis. Respiration 2005;72:32–38.
13.
Hu H, Stein-Streilein J: Hapten-immune pulmonary interstitial fibrosis (HIPIF) in mice requires both CD4+ and CD8+ T lymphocytes. J Leukoc Biol 1993;54:414–422.
14.
Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138–147.
15.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165:277–304.
16.
Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE: A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986;133:97–103.
17.
Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5–40.
18.
Kazerooni EA, Martinez FJ, Flint A, et al: Thin-section CT obtained at 10-mm increments versus three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997;169:977–983.
19.
Howard CV, Reed MG: Unbiased stereology: three-dimensional measurement in microscopy; in Microscopy Handbooks, vol 41. New York, Springer-Verlag, 1998.
20.
Norusis MJ: SPSS for Windows (10.0). Chicago, SPSS, 2002.
21.
Sleijfer S: Bleomycin-induced pneumonitis. Chest 2001;120:617–624.
22.
Campell DA, Poulter LW, Janossy G, du Bois RM: Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity. Thorax 1985;40:405–411.
23.
White SR, Lazar HM, Thannichal JV: Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J Pathol 2003;201:343–354.
24.
Haslam LP: Evaluation of alveolitis by studies of lung biopsies. Lung 1990;168(suppl): 984–992.
25.
Paradis LI, Dauber HJ, Rabin SB: Lymphocyte phenotypes in bronchoalveolar lavage and lung biopsies in sarcoidosis and idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986;133:855–860.
26.
Yamadori I, Fujiata J, Kajitani H, Tokuda M, Yang Y, Ohtsuki Y, Yoshinouchi T, Kamei T, Ishida T: Lymphocytic subsets in lung tissue of non-specific interstitial pneumonia and pulmonary fibrosis associated with collagen vascular disorders: correlation with CD4/CD8 ratio in bronchoalveolar lavage. Lung 2000;178:361–370.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.